ARLINGTON, Va., January 30, 2018 – Co-sponsors of the 2018 Multidisciplinary Head and Neck Cancers Symposium announced today that four abstracts will be highlighted in the meeting's official press program. Researchers will present the findings of these studies in an online news briefing for media professionals on Tuesday, February 13, 2018, from 12:00 to 1:15 p.m. Eastern time. Interested reporters can register to cover the meeting and receive connection information for the news briefing at www.astro.org/HNpress.
The news briefing will feature the following studies:
A randomized, open-label, multicenter, global phase 2 study of durvalumab (D), tremelimumab (T), or D Plus T in patients with PD-L1 low/negative recurrent or metastatic head and neck squamous cell carcinoma: CONDOR (Abstract 1); Dr. Lillian Siu, Princess Margaret Cancer Centre
Ad Statistics
Times Displayed: 22487
Times Visited: 455 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Safety evaluation of nivolumab concomitant with platinum-based chemoradiotherapy for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504 (Abstract 2); Dr. Maura Gillison, University of Texas MD Anderson Cancer Center
OPTIMA—A phase II trial of induction chemotherapy response-stratified RT dose and volume de-escalation for HPV+ oropharynx cancer: Efficacy, toxicity, and HPV subtype analysis (Abstract 5); Dr. Tanguy Seiwert, University of Chicago
A phase II trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting (Abstract 8); Dr. Marcia Brose, University of Pennsylvania School of Medicine
The 2018 Multidisciplinary Head and Neck Cancers Symposium will take place February 15-17 at the Westin Kierland Resort and Spa in Scottsdale, Arizona. Researchers will present peer-reviewed abstracts on new combination therapies, targeted therapies, immunotherapy, advanced radiation and surgical techniques, new staging systems, treatment guidelines and supportive care. The meeting is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and the American Head & Neck Society (AHNS).
Credentialed journalists from accredited news organizations are invited to attend and report on the symposium, or to cover the meeting remotely. Reporters registered by February 9, 2018, will receive an embargoed press kit. Additional information, the registration form and housing information are available online.
An on-site press office in the Parke Room of the Westin Kierland will be open February 15-16 during meeting hours. Rooms also are available to reserve for media interviews on a first-come, first-serve basis.
